Photo from Paz Polak/LinkedIn
Sep 3, 2023, 17:26
Paz Polak: In a correspondence letter we wrote for the NEJM, we suggested that testing for POLE, and even better, checking for POLE-associated mutational signatures.
Paz Polak, VP of Computational Biology, C2i Genomics, recently posted on LinkedIn:
“In a correspondence letter we wrote for the New England Journal of Medicine (NEJM), we suggested that testing for POLE, and even better, checking for POLE-associated mutational signatures for example by whole-genome sequencing, could help understand why some endometrial patients with mismatch repair proficiency respond to immunotherapies. I advocate that every patient with an aggressive endometrial tumor should have whole-genome sequencing. This can guide treatments, whether it’s immunotherapies, PARP inhibitors, or other therapies.”
Source: Paz Polak/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 14:06
Dec 21, 2024, 13:46
Dec 21, 2024, 13:40
Dec 21, 2024, 13:33